{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:26:36Z","timestamp":1774293996779,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,3,25]],"date-time":"2005-03-25T00:00:00Z","timestamp":1111708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1007\/s00280-004-0924-9","type":"journal-article","created":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T15:10:03Z","timestamp":1111677003000},"page":"91-96","source":"Crossref","is-referenced-by-count":30,"title":["Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy"],"prefix":"10.1007","volume":"56","author":[{"given":"Toshiaki","family":"Sendo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ikesue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoo","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryozo","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,3,25]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2165\/00002018-199512030-00005","volume":"12","author":"RJ Bitton","year":"1995","unstructured":"Bitton RJ, Figg WD, Reed E (1995) A preliminary risk-benefit assessment of paclitaxel. Drug Saf 12:196\u2013208","journal-title":"Drug Saf"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/jnci\/88.7.463","volume":"88","author":"DK Boehm","year":"1996","unstructured":"Boehm DK, Maksymiuk AW (1996) Paclitaxel premedication regimens. J Natl Cancer Inst 88:463\u2013465","journal-title":"J Natl Cancer Inst"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1023\/A:1008207025430","volume":"8","author":"MA Bookman","year":"1997","unstructured":"Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF (1997) Short-course intravenous prophylaxis for paclitaxel related hypersensitivity reactions. Ann Oncol 8:611\u2013614","journal-title":"Ann Oncol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2002.20.5.1232","volume":"20","author":"MG Cantu","year":"2002","unstructured":"Cantu MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell\u2019Anna T, Torri V, Colombo N (2002) Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20:1232\u20131237","journal-title":"J Clin Oncol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1179\/joc.1999.11.5.407","volume":"11","author":"G Cormio","year":"1999","unstructured":"Cormio G, Di Vagno G, Melilli GA, Cazzolla A, Di Gesu G, Carriero C, Cramarossa D, Loverro G, Selvaggi L (1999) Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemother 11:407\u2013409","journal-title":"J Chemother"},{"key":"CR8","first-page":"317","volume":"16","author":"G Decorti","year":"1996","unstructured":"Decorti G, Bartoli Klugmann F, Candussio L, Baldini L (1996) Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin. Anticancer Res 16:317\u2013320","journal-title":"Anticancer Res"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1046\/j.1365-2745.2002.01457.x","volume":"32","author":"I Ehlers","year":"2002","unstructured":"Ehlers I, Hipler UC, Zuberbier T, Worm M (2002) Ethanol as a cause of hypersensitivity reactions to alcoholic beverages. Clin Exp Allergy 32:1231\u20131235","journal-title":"Clin Exp Allergy"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","volume":"12","author":"EA Eisenhauer","year":"1994","unstructured":"Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N (1994) European Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654\u20132666","journal-title":"J Clin Oncol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0091-6749(96)70281-6","volume":"97","author":"DM Essayan","year":"1996","unstructured":"Essayan DM, Kagey-Sobotka A, Colarusso PJ, Lichtenstein LM, Ozols RF, King ED (1996) Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 97:42\u201346","journal-title":"J Allergy Clin Immunol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1096\/fasebj.10.5.8621060","volume":"10","author":"MY Farhat","year":"1996","unstructured":"Farhat MY, Lavigne MC, Ramwell PW (1996) The vascular protective effects of estrogens. FASEB J 10:615\u2013624","journal-title":"FASEB J"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000227707","volume":"54","author":"K Furuse","year":"1997","unstructured":"Furuse K, Naka N, Takada M, Kinuwaki E, Kudo S, Takada Y, Yamakido M, Yamamoto H, Fukuoka M (1997) Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group. Oncology 54:298\u2013303","journal-title":"Oncology"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jnci\/87.15.1169","volume":"87","author":"L Gianni","year":"1995","unstructured":"Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, Fulfaro F, Caraceni A, Martini C, Laffranchi A (1995) Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169\u20131175","journal-title":"J Natl Cancer Inst"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/1097-0142(20011015)92:8<2142::AID-CNCR1556>3.0.CO;2-R","volume":"92","author":"FA Greco","year":"2001","unstructured":"Greco FA, Burris HA III, Gray JR, Raefsky EL, Dobbs C, Smith S, Rinaldi D, Morrissey LH, Erland JB, Litchy S, Hainsworth JD (2001) Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research Network. Cancer 92:2142\u20132147","journal-title":"Cancer"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0936-6555(05)80367-X","volume":"6","author":"HJ Guchelaar","year":"1994","unstructured":"Guchelaar HJ, ten Napel CH, de Vries EG, Mulder NH (1994) Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol 6:40\u201348","journal-title":"Clin Oncol"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1269::AID-CNCR8>3.0.CO;2-I","volume":"85","author":"JD Hainsworth","year":"1999","unstructured":"Hainsworth JD, Burris HA III, Erland JB, Morrissey LH, Meluch AA, Kalman LA, Hon JK, Scullin DC Jr, Smith SW, Greco FA (1999) Phase I\/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer 85:1269\u20131276","journal-title":"Cancer"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/cncr.10951","volume":"95","author":"C Hsu","year":"2002","unstructured":"Hsu C, Huang CS, Chao TY, Lu YS, Bu CF, Chen MM, Chang KJ, Cheng AL (2002) Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naive patients with locally advanced or metastatic breast carcinoma. Cancer 95:2044\u20132050","journal-title":"Cancer"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1006036923200","volume":"16","author":"Y Ito","year":"1998","unstructured":"Ito Y, Horikoshi N, Watanabe T, Sasaki Y, Tominaga T, Okawa T, Tabei T, Kuraishi Y, Tamura K, Abe R, Kitajima M, Yamaguchi S, Kobayashi T, Koyama H, Orita K, Takashima S, Nomura Y, Ogawa M (1998) Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group. Invest New Drugs 16:183\u2013190","journal-title":"Invest New Drugs"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1345\/aph.10287","volume":"35","author":"PE Kintzel","year":"2001","unstructured":"Kintzel PE (2001) Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother 35:1114\u20131117","journal-title":"Ann Pharmacother"},{"key":"CR21","first-page":"1015","volume":"73","author":"J Kobierski","year":"2002","unstructured":"Kobierski J, Majdak E, Mielcarek P, Emerich J (2002) Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma. Ginekol Pol 73:1015\u20131020","journal-title":"Ginekol Pol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1006\/gyno.2001.6546","volume":"84","author":"JS Kwon","year":"2002","unstructured":"Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, Trim K (2002) A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 84:420\u2013425","journal-title":"Gynecol Oncol"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1023\/A:1008272114546","volume":"9","author":"J Lokich","year":"1998","unstructured":"Lokich J, Anderson N (1998) Paclitaxel hypersensitivity reactions: a role for docetaxel substitution. Ann Oncol 9:573\u2013574","journal-title":"Ann Oncol"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF01964882","volume":"7","author":"W Lorenz","year":"1977","unstructured":"Lorenz W, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, Doenicke A (1977) Histamine release in dogs by Cremophor El and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 7:63\u201367","journal-title":"Agents Actions"},{"issue":"S15","key":"CR25","first-page":"26","volume":"24","author":"M Markman","year":"1997","unstructured":"Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1997) Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience. Semin Oncol 24(S15):26\u201329","journal-title":"Semin Oncol"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","volume":"18","author":"M Markman","year":"2000","unstructured":"Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18:102\u2013105","journal-title":"J Clin Oncol"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1006\/gyno.1998.4993","volume":"69","author":"JP Micha","year":"1998","unstructured":"Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV (1998) Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol 69:122\u2013124","journal-title":"Gynecol Oncol"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.1996.14.1.142","volume":"14","author":"MJ Millward","year":"1996","unstructured":"Millward MJ, Bishop JF, Friedlander M, Levi JA, Goldstein D, Olver IN, Smith JG, Toner GC, Rischin D, Bell DR (1996) Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 14:142\u2013148","journal-title":"J Clin Oncol"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00001813-200008000-00004","volume":"11","author":"JF Morere","year":"2000","unstructured":"Morere JF, Piperno-Neumann S, Coulon MA, Vaylet F, L\u2019Her P, Brunet A, Quinaux E, Breau JL (2000) Dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Anticancer Drugs 11:541\u2013548","journal-title":"Anticancer Drugs"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1005882314735","volume":"45","author":"AM Murad","year":"1997","unstructured":"Murad AM, Guimaraes RC, Amorim WC, Morici AC, Ferreira-Filho AF, Schwartsmann G (1997) Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. Breast Cancer Res Treat 45:47\u201353","journal-title":"Breast Cancer Res Treat"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1023\/A:1010682916808","volume":"19","author":"B Nuijen","year":"2001","unstructured":"Nuijen B, Bouma M, Schellens JH, Beijnen JH (2001) Progress in the development of alternative pharmaceutical formulations of taxanes. Invest New Drugs 19:143\u2013153","journal-title":"Invest New Drugs"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/S0959-8049(03)00319-8","volume":"39","author":"ME O\u2019Brien","year":"2003","unstructured":"O\u2019Brien ME, Splinter T, Smit EF, Biesma B, Krzakowski M, Tjan-Heijnen VC, Van Bochove A, Stigt J, Smid-Geirnaerdt MJ, Debruyne C, Legrand C, Giaccone G (2003) EORTC Lung Cancer Group. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958). Eur J Cancer 39:1416\u20131422","journal-title":"Eur J Cancer"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1997.4906","volume":"68","author":"JK Olson","year":"1998","unstructured":"Olson JK, Sood AK, Sorosky JI, Anderson B, Buller RE (1998) Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynecol Oncol 68:25\u201328","journal-title":"Gynecol Oncol"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1054\/bjoc.2001.1897","volume":"85","author":"A Riccardi","year":"2001","unstructured":"Riccardi A, Pugliese P, Danova M, Brugnatelli S, Grasso D, Giordano M, Bernardo G, Giardina G, Fava S, Montanari G, Pedrotti C, Trotti G, Rinaldi E, Poli MA, Tinelli C (2001) A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97\/01). Br J Cancer 85:141\u2013146","journal-title":"Br J Cancer"},{"issue":"2 Suppl 1","key":"CR35","first-page":"136","volume":"9","author":"F Robert","year":"1999","unstructured":"Robert F, Childs HA, Spencer SA, Redden DT, Hawkins MM (1999) Phase I\/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity. Semin Radiat Oncol 9 (2 Suppl 1):136\u2013147","journal-title":"Semin Radiat Oncol"},{"issue":"4 Suppl 3","key":"CR36","first-page":"16","volume":"20","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Donehower RC (1993) The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 20 (4 Suppl 3):16\u201325","journal-title":"Semin Oncol"},{"issue":"4 Suppl 3","key":"CR37","first-page":"1","volume":"20","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20 (4 Suppl 3):1\u201315","journal-title":"Semin Oncol"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2710.2003.00529.x","volume":"28","author":"N Sakai","year":"2003","unstructured":"Sakai N, Sendo T, Itoh Y, Hirakawa Y, Takeshita A, Oishi R (2003) Delayed adverse reactions to iodinated radiographic contrast media after coronary angiography: a search for possible risk factors. J Clin Pharm Ther 28:505\u2013512","journal-title":"J Clin Pharm Ther"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jnci\/90.4.300","volume":"90","author":"J Szebni","year":"1998","unstructured":"Szebni J, Muggia FM, Alving CR (1998) Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90:300\u2013306","journal-title":"J Natl Cancer Inst"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00004424-200103000-00001","volume":"36","author":"K Tominaga","year":"2001","unstructured":"Tominaga K, Kataoka Y, Sendo T, Furuta W, Niizeki M, Oishi R (2001) Contrast medium-induced pulmonary vascular hyperpermeability is aggravated in a rat climacterium model. Invest Radiol 36:131\u2013135","journal-title":"Invest Radiol"},{"issue":"4 Suppl 2","key":"CR42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0749-2081(16)30036-5","volume":"9","author":"FE Walker","year":"1993","unstructured":"Walker FE (1993) Paclitaxel (Taxol): side effects and patient education issues. Semin Oncol Nurs 9 (4 Suppl 2):6\u201310","journal-title":"Semin Oncol Nurs"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"RB Weiss","year":"1990","unstructured":"Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263\u20131268","journal-title":"J Clin Oncol"},{"key":"CR44","first-page":"2486","volume":"47","author":"PH Wiernik","year":"1987","unstructured":"Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486\u20132493","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0924-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-004-0924-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0924-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:10Z","timestamp":1559037970000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-004-0924-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,25]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1007\/s00280-004-0924-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,25]]}}}